Affiliation:
1. Scientific Centre for Expert Evaluation of Medicinal Products
Abstract
Currently, there is an increase in pre- and post-approval testing of medicinal products containing diosmin and hence a need to unify approaches to standardisation of this group of pharmaceuticals. Moreover, the State Pharmacopoeia of the Russian Federation lacks a monograph for these products.The aim of the study was to determine an approach to standardisation of medicinal products containing diosmin.Materials and methods: the study analysed scientific publications, as well as monographs of leading foreign pharmacopoeias. Experimental work was carried out using samples of diosmin-containing pharmaceuticals in the form of 500 and 1000 mg film-coated tablets produced by Russian and foreign manufacturers. The study involved high performance liquid chromatography with UV detection using an Agilent 1260 Infinity II liquid chromatography system with a diode array detector. The following reference standards were used: a diosmin RS, USP grade; a hesperidin CRS, Ph. Eur. Grade; and a diosmin CRS for testing chromatography system suitability for identification of impurities A, B, C, D, E, and F, Ph. Eur. grade.Results: the authors reviewed quality requirements for pharmaceutical products containing diosmin and analysed experimental data obtained during pre- and post-approval testing of Russian and foreign medicines. The comparison of regulatory documents for registered diosmin-containing medicinal products showed a difference in approaches to assessing the contents of related substances and active pharmaceutical ingredients. Having analysed the literature, experimental data and regulatory requirements for standardisation of diosmin-containing pharmaceuticals, the authors recommended an approach to standardisation. According to the approach, concomitant flavonoids (hesperidin, isorchoifolin, linarin, and diosmetin) contributing to the pharmacological activity of a medicinal product are specified as part of Assay, and process-related by-products (impurities A and D) are specified and evaluated as part of Related substances tests.Conclusion: the authors propose to evaluate the contents of concomitant flavonoids (hesperidin, isorchoifolin, linarin, diosmetin) under Assay and to specify impurities A and D, as well as single unidentified impurities and total amount of impurities under Related substances.
Reference14 articles.
1. Tarakhovsky YuS, Kim YuA, Abdrasilov BS, Muzafarov EN. Flavonoids: biochemistry, biophysics, medicine. Pushchino: Synchrobook; 2013 (In Russ.)
2. Teucrium chamaedrys L. — Wall germander. In: Gubanov IA, Kiseleva KV, Novikov VS, Tikhomirov VN. Illustrated guide to plants of Central Russia. V. 3. Moscow: Association of scientific publications of KMK; 2004. P. 158 (In Russ.)
3. Oesterle OA, Wander G. Über das „Hesperidin” einiger Pflanzen. Helv Chim Acta. 1925;8(1):519–36. https://doi.org/10.1002/hlca.19250080179
4. Talibov OB. Diosmin in the treatment of venous disease: pharmacokinetics and pharmacodynamics. Khirurgiya. Zhurnal im. N.I. Pirogova = Pirogov Journal of Surgery. 2019;(3):135–40 (In Russ.) https://doi.org/10.17116/hirurgia2019031135
5. Ivanova EV, Chereshneva ND. Angioprotectors: diosmin, diosmin+hesperidin. Comparative characteristics of drugs. In: Modern problems of medicine and natural sciences. Collection of articles of the international scientific conference. Yoshkar-Ola: Mari State University; 2019. P. 94–7 (In Russ.)